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The physiologic stemness of hematopoietic stem 
cells (HSC) relies on mechanisms constitutively active 
under steady state and is fundamental to maintain a 
lifelong HSC reservoir. On the other side, similar stemness 
features sustained by partially overlapping molecular 
circuits, which have recently come into focus, confer 
aggressive aggressiveness in leukemia clones.
Suppressor of Cytokine Signalling 2 (SOCS2) 
belongs to the SOCS family, comprising eight members 
(SOCS1-7 and CIS) with similar structures, which are 
induced upon JAK/STAT activation and function as 
negative regulators. Recent evidences have demonstrated 
that SOCS2 is endowed with immunological functions 
in differentiated cells but no apparent functions were 
identified in HSC despite its expression in steady state 
condition.
Combining analysis of human HSC malignancies 
and studies on murine HSC under steady state and 
stress conditions [1], we have recently identified a dual 
involvement of SOCS2 in the regulation of HSC functions 
in different contexts and demonstrated a novel regulatory 
mechanism for SOCS2 expression in HSC. 
In mice under hematopoietic stress conditions, 
such as after 5-Fluorouracil-induced myeloablation, 
hematopoietic cytokines are rapidly produced to sustain 
bone marrow (BM) recovery. This event induces activation 
of the JAK-STAT5 pathway consequently upregulating 
SOCS2. Such negative feedback loop avoids excessive 
HSC proliferation and eventually the exhaustion of HSC 
functions.
This regulatory function of SOCS2 is completely 
novel, while the JAK-STAT dependency for its expression 
is common to the regulatory loop involving other SOCS 
proteins as well as SOCS2 in other contexts [2]. 
Also, we uncovered SOCS2 involvement in 
hematopoietic malignancies. High SOCS2 expression 
characterized the BM of chronic myeloid leukemia 
(CML) patients and increased along clone progression 
toward blast crisis. The highest and widespread SOCS2 
expression in BM hematopoietic populations was 
associated with aggressive acute leukemia subsets, namely 
acute myeloid (AML) and lymphoblastic leukemias (ALL) 
with MLL rearrangments and BCR/ABL abnormalities. In 
AML patients, high SOCS2 was significatively associated 
with poor prognosis.
In AML and ALL patients, high SOCS2 expression 
also positively correlated with a list of genes that 
significanly overlapped with leukemic stemness gene 
signatures [3], suggesting that SOCS2 and hematopoietic 
stemness can be associated in the context of hematopietic 
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Figure1: Schematic representation of SOC2 involvement in different hematopoietic settings: normal, steady-state 
hematopoiesis; myeloablation-induced stress hematopoiesis; malignant hematopoiesis. The function of SOCS2 in these 
settings varies from hematopoietic regulation to stemness program induction according to its control by either STAT-dependent or MEF2C-
dependent regulation.
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malignancies. Normal HSC and leukemic stem cells 
(LSC) share some common molecular programs and, 
conceivably, similar molecular mechanisms could regulate 
SOCS2 in these populations. 
Our analysis of public gene expression profiles of 
AML and ALL excluded that SOCS2 expression could 
be ascribed only to JAK-STAT pathways activation and 
suggests that alternative STAT-independent molecular 
programs should be involved. To our knowledge, this is 
the first indication of STAT-independent regulation of 
SOCS proteins, raising a question on whether similar 
regulation might occur for other SOCS family members. 
Such STAT-independent mechanism might explain the 
expression of SOCS2 in acute leukemia subsets with 
MLL rearrangements, which are not strictly associated to 
constitutive STATs activation. 
Computational analysis revealed a novel regulatory 
network for SOCS2 reliant on MEF2C, a transcriptional 
factor already associated to ALL with MLL rearrangement 
[4]. MEF2C-dependent SOCS2 regulation was confirmed 
in vitro in murine hematopoietic lineage-c-kit+Sca1+ (LSK) 
BM precursors upon transduction with Mef2c. Such 
Mef2c-requirement for Socs2 expression in steady state 
condition can be overcome by cytokine stimulation in case 
of hematopoietic stress. 
In conclusion SOCS2 appears to take part into 
a stemness program that is MEF2C-dependent while 
STAT-independent, a condition than can be inverted in 
case of stress-induced hematopoiesis. Moreover, the 
program fronted by MEF2C confers stemness features 
to the leukemic clones of AML and of ALL with MLL 
rearrangement, and is detrimental for the patients. 
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